NCT01352962View on ClinicalTrials.gov

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2011

Primary Completion Date

February 7, 2017

Study Completion Date

July 6, 2018

Conditions

Urethral NeoplasmsNeoplasms, UrethralCancer of the UrethraUrethral Cancer

Interventions

DRUG

Gemcitabine

1,000mg/m2 IVPB over 30 min x 1

DRUG

Carboplatin

AUC 5\*\* IVPB over 30 min x 1

DRUG

Lenalidomide

Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01352962 - Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | Biotech Hunter | Biotech Hunter